Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis.

Wang Y, Cai KQ, Smith ER, Yeasky TM, Moore R, Ganjei-Azar P, Klein-Szanto AJ, Godwin AK, Hamilton TC, Xu XX.

Mol Cell Biol. 2016 Aug 26;36(18):2418-30. doi: 10.1128/MCB.00202-16. Print 2016 Sep 15.

2.

Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy.

Williams RM, Flesken-Nikitin A, Ellenson LH, Connolly DC, Hamilton TC, Nikitin AY, Zipfel WR.

Transl Oncol. 2010 Jun 1;3(3):181-94.

3.

Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.

Liang S, Yang N, Pan Y, Deng S, Lin X, Yang X, Katsaros D, Roby KF, Hamilton TC, Connolly DC, Coukos G, Zhang L.

PLoS One. 2009;4(1):e4295. doi: 10.1371/journal.pone.0004295. Epub 2009 Jan 27.

4.

Vitamin A metabolism is impaired in human ovarian cancer.

Williams SJ, Cvetkovic D, Hamilton TC.

Gynecol Oncol. 2009 Mar;112(3):637-45. doi: 10.1016/j.ygyno.2008.11.015. Epub 2008 Dec 25.

5.

Platinum resistance: the role of DNA repair pathways.

Martin LP, Hamilton TC, Schilder RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1291-5. doi: 10.1158/1078-0432.CCR-07-2238. Review.

6.

Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC.

Cancer Biol Ther. 2007 Nov;6(11):1717-25. Epub 2007 Aug 3.

PMID:
17986851
7.

A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.

Yang WL, Cai KQ, Smedberg JL, Smith ER, Klein-Szanto A, Hamilton TC, Xu XX.

Am J Pathol. 2007 Apr;170(4):1325-36.

8.

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR.

Cancer Res. 2007 Mar 15;67(6):2408-13.

9.

Recent insights into platinum drug resistance in cancer.

Johnson SW, Ferry KV, Hamilton TC.

Drug Resist Updat. 1998;1(4):243-54.

PMID:
16904407
10.

10th Biennial Helene Harris Memorial Trust meeting.

Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND.

Cancer Res. 2006 Mar 15;66(6):2904-6.

11.

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.

Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW.

Br J Cancer. 2005 Mar 28;92(6):1149-58.

12.

Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.

Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A.

Gynecol Oncol. 2004 Dec;95(3):449-55.

PMID:
15581945
13.

Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia.

Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C.

Cancer Res. 2004 Nov 15;64(22):8177-83.

14.

Pathology of Ovarian Neoplasms in Genetically Modified Mice.

Nikitin AY, Connolly DC, Hamilton TC.

Comp Med. 2004 Feb;54(1):26-8. Review. No abstract available.

PMID:
15382342
15.

Focus on epithelial ovarian cancer.

Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC.

Cancer Cell. 2004 Jan;5(1):19-24. No abstract available.

16.

Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.

Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX.

Cancer. 2003 Dec 15;98(12):2607-23.

17.

Translational research in ovarian cancer: a must.

Hamilton TC, Connolly DC, Nikitin AY, Garson K, Vanderhyden BC.

Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:220-30. Review.

PMID:
14656284
18.

Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis.

Capo-chichi CD, Roland IH, Vanderveer L, Bao R, Yamagata T, Hirai H, Cohen C, Hamilton TC, Godwin AK, Xu XX.

Cancer Res. 2003 Aug 15;63(16):4967-77.

19.

Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells.

Abdollahi A, Gruver BN, Patriotis C, Hamilton TC.

Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97.

PMID:
12849999
20.

Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1.

Garson K, Macdonald E, Dubé M, Bao R, Hamilton TC, Vanderhyden BC.

J Soc Gynecol Investig. 2003 May;10(4):244-50.

PMID:
12759154
21.

Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC.

Cancer Res. 2003 Mar 15;63(6):1389-97.

22.

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.

Cancer Res. 2003 Mar 15;63(6):1311-6.

23.

Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer.

Cvetković D, Williams SJ, Hamilton TC.

Clin Cancer Res. 2003 Mar;9(3):1013-20.

24.

Specific keynote: chemoprevention of ovarian cancer: the journey begins.

Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC Jr, Brewer MA.

Gynecol Oncol. 2003 Jan;88(1 Pt 2):S59-66; discussion S67-70. Review. No abstract available.

PMID:
12586088
25.

LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer.

Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, Hamilton TC.

J Biol Chem. 2003 Feb 21;278(8):6041-9. Epub 2002 Dec 6.

26.

Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis.

Yang DH, Smith ER, Roland IH, Sheng Z, He J, Martin WD, Hamilton TC, Lambeth JD, Xu XX.

Dev Biol. 2002 Nov 1;251(1):27-44.

PMID:
12413896
27.

Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.

Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX.

Cancer. 2002 Oct 15;95(8):1802-15.

28.

Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity.

Yang DH, Smith ER, Cohen C, Wu H, Patriotis C, Godwin AK, Hamilton TC, Xu XX.

Cancer. 2002 May 1;94(9):2380-92.

30.

Activation of cancer-specific gene expression by the survivin promoter.

Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC.

J Natl Cancer Inst. 2002 Apr 3;94(7):522-8.

PMID:
11929953
31.

Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium.

Roberts D, Williams SJ, Cvetkovic D, Weinstein JK, Godwin AK, Johnson SW, Hamilton TC.

DNA Cell Biol. 2002 Jan;21(1):11-9.

PMID:
11879576
32.

Targeted gene therapy of ovarian cancer using an ovarian-specific promoter.

Bao R, Selvakumaran M, Hamilton TC.

Gynecol Oncol. 2002 Feb;84(2):228-34.

PMID:
11812079
33.

Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells.

Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX.

J Biol Chem. 2001 Dec 14;276(50):47303-10. Epub 2001 Sep 27.

34.

The role of molecular biology in understanding ovarian cancer initiation and progression.

Bingham C, Roberts D, Hamilton TC.

Int J Gynecol Cancer. 2001;11 Suppl 1:7-11. Review.

PMID:
11488996
35.

Disassociation of MAPK activation and c-Fos expression in F9 embryonic carcinoma cells following retinoic acid-induced endoderm differentiation.

Smith ER, Smedberg JL, Rula ME, Hamilton TC, Xu XX.

J Biol Chem. 2001 Aug 24;276(34):32094-100. Epub 2001 Jun 11.

36.

Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.

Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC.

Cancer Res. 2001 Feb 15;61(4):1291-5.

37.

Recent insights into drug resistance in ovarian cancer.

Hamilton TC, Johnson SW.

Methods Mol Med. 2001;39:89-106. doi: 10.1385/1-59259-071-3:89.

PMID:
21340760
38.

Vascular endothelial growth factor in ovarian cancer.

Hazelton DA, Hamilton TC.

Curr Oncol Rep. 1999 Sep;1(1):59-63. Review.

PMID:
11122799
39.

The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.

Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR.

Cancer Res. 2000 Oct 1;60(19):5390-4.

40.

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

Ferry KV, Hamilton TC, Johnson SW.

Biochem Pharmacol. 2000 Nov 1;60(9):1305-13.

PMID:
11008124
41.

[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Tropé C, Tuxen MK, Vergote I, Vermorken JB, Willemse PH.

Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83. Review. French. No abstract available.

PMID:
10996969
42.
44.
45.

Advanced epithelial ovarian cancer: 1998 consensus statements.

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al.

Ann Oncol. 1999;10 Suppl 1:87-92.

PMID:
10219460
46.

Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?

Hamilton TC, Berek JS, Kaye SB.

Ann Oncol. 1999;10 Suppl 1:69-73. Review.

PMID:
10219457
47.

New non-cytotoxic approaches to ovarian cancer.

Kaye SB, Eisenhauer EA, Hamilton TC.

Ann Oncol. 1999;10 Suppl 1:65-8. Review.

PMID:
10219456
48.

Re: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.

Hamilton TC.

J Natl Cancer Inst. 1999 Apr 7;91(7):650-1. No abstract available.

PMID:
10203291
49.

Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells.

Ferry KV, Fink D, Johnson SW, Nebel S, Hamilton TC, Howell SB.

Biochem Pharmacol. 1999 Apr 15;57(8):861-7.

PMID:
10086318
50.

Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells.

Abdollahi A, Getts LA, Sonoda G, Miller PD, Taguchi T, Godwin AK, Testa JR, Hamilton TC.

J Soc Gynecol Investig. 1999 Jan-Feb;6(1):32-40.

PMID:
10065424

Supplemental Content

Loading ...
Support Center